Hauser RA - Search Results

1

Scales for Antipsychotic-Associated Movement Disorders: Systematic Review, Critique, and Recommendations.

Martino D, Karnik V, Bhidayasiri R, Hall DA, Hauser RA, Macerollo A, Pringsheim TM, Truong D, Factor SA, Skorvanek M, Schrag A; Members of the IPMDS Rating Scales Review Committee. Martino D, et al. Among authors: hauser ra. Mov Disord. 2023 Jun;38(6):1008-1026. doi: 10.1002/mds.29392. Epub 2023 Apr 20. Mov Disord. 2023. PMID: 37081740

2

Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD.

Hauser RA, Hubble JP, Truong DD; Istradefylline US-001 Study Group. Hauser RA, et al. Neurology. 2003 Aug 12;61(3):297-303. doi: 10.1212/01.wnl.0000081227.84197.0b. Neurology. 2003. PMID: 12913187 Clinical Trial.

3

Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study.

Truong D, Duane DD, Jankovic J, Singer C, Seeberger LC, Comella CL, Lew MF, Rodnitzky RL, Danisi FO, Sutton JP, Charles PD, Hauser RA, Sheean GL. Truong D, et al. Among authors: hauser ra. Mov Disord. 2005 Jul;20(7):783-91. doi: 10.1002/mds.20403. Mov Disord. 2005. PMID: 15736159 Clinical Trial.

4

Use of nutritional supplements in Parkinson's disease patients.

Wolfrath SC, Borenstein AR, Schwartz S, Hauser RA, Sullivan KL, Zesiewicz TA. Wolfrath SC, et al. Among authors: hauser ra. Mov Disord. 2006 Aug;21(8):1098-101. doi: 10.1002/mds.20902. Mov Disord. 2006. PMID: 16639735

5

Treatment of early Parkinson's disease. Part 1.

Simuni T, Lyons KE, Pahwa R, Hauser RA, Comella C, Elmer L, Weintraub D. Simuni T, et al. Among authors: hauser ra. Eur Neurol. 2009;61(4):193-205. doi: 10.1159/000197103. Epub 2009 Jan 29. Eur Neurol. 2009. PMID: 19176960 Free article. Review.

6

Treatment of early Parkinson's disease. Part 2.

Simuni T, Lyons KE, Pahwa R, Hauser RA, Comella C, Elmer L, Weintraub D. Simuni T, et al. Among authors: hauser ra. Eur Neurol. 2009;61(4):206-15. doi: 10.1159/000197104. Epub 2009 Jan 29. Eur Neurol. 2009. PMID: 19176961 Free article. Review.

7

Task force report on scales to assess dyskinesia in Parkinson's disease: critique and recommendations.

Colosimo C, Martínez-Martín P, Fabbrini G, Hauser RA, Merello M, Miyasaki J, Poewe W, Sampaio C, Rascol O, Stebbins GT, Schrag A, Goetz CG. Colosimo C, et al. Among authors: hauser ra. Mov Disord. 2010 Jul 15;25(9):1131-42. doi: 10.1002/mds.23072. Mov Disord. 2010. PMID: 20310033 Review.

8

Which dyskinesia scale best detects treatment response?

Goetz CG, Stebbins GT, Chung KA, Hauser RA, Miyasaki JM, Nicholas AP, Poewe W, Seppi K, Rascol O, Stacy MA, Nutt JG, Tanner CM, Urkowitz A, Jaglin JA, Ge S. Goetz CG, et al. Among authors: hauser ra. Mov Disord. 2013 Mar;28(3):341-6. doi: 10.1002/mds.25321. Epub 2013 Feb 6. Mov Disord. 2013. PMID: 23390076 Clinical Trial.

9

Long-term safety and efficacy of preladenant in subjects with fluctuating Parkinson's disease.

Factor SA, Wolski K, Togasaki DM, Huyck S, Cantillon M, Ho TW, Hauser RA, Pourcher E. Factor SA, et al. Among authors: hauser ra. Mov Disord. 2013 Jun;28(6):817-20. doi: 10.1002/mds.25395. Epub 2013 Apr 15. Mov Disord. 2013. PMID: 23589371 Clinical Trial.

10

Phase II safety, tolerability, and dose selection study of isradipine as a potential disease-modifying intervention in early Parkinson's disease (STEADY-PD).

Parkinson Study Group. Parkinson Study Group. Mov Disord. 2013 Nov;28(13):1823-31. doi: 10.1002/mds.25639. Epub 2013 Sep 30. Mov Disord. 2013. PMID: 24123224 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

332 results

Search Page